DISCO CORPORATION UNSP ADR EACH REP 0.20 ORS (DSCSY) Analysts See $0.46 EPS; Theravance Biopharma (TBPH) Had 6 Analysts Last Week

July 17, 2017 - By Marguerite Chambers

Among 7 analysts covering Theravance Biopharma (NASDAQ:TBPH), 6 have Buy rating, 1 Sell and 0 Hold. Therefore 86% are positive. Theravance Biopharma had 9 analyst reports since August 12, 2015 according to SRatingsIntel. The rating was maintained by Robert W. Baird with “Neutral” on Wednesday, August 12. Leerink Swann initiated it with “Outperform” rating and $26 target in Thursday, May 12 report. The stock has “Overweight” rating by Piper Jaffray on Thursday, November 3. As per Monday, August 29, the company rating was initiated by Evercore. The company was initiated on Wednesday, December 21 by Needham. As per Wednesday, October 12, the company rating was downgraded by Robert W. Baird. The firm earned “Buy” rating on Monday, June 20 by Guggenheim. See Theravance Biopharma Inc (NASDAQ:TBPH) latest ratings:

16/06/2017 Broker: Inc. – Ordinary Shares Rating: Cantor Fitzgerald 55

Analysts expect DISCO CORPORATION UNSP ADR EACH REP 0.20 ORS (OTCMKTS:DSCSY) to report $0.46 EPS on August, 3.DSCSY’s profit would be $82.45M giving it 18.32 P/E if the $0.46 EPS is correct. It is down 0.00% since July 17, 2016 and is . It has underperformed by 16.70% the S&P500.

About 127,432 shares traded. Theravance Biopharma Inc (NASDAQ:TBPH) has risen 89.85% since July 17, 2016 and is uptrending. It has outperformed by 73.15% the S&P500.

Since March 3, 2017, it had 0 buys, and 2 insider sales for $1.30 million activity. The insider HAUMANN BRETT K sold 14,000 shares worth $440,975. Another trade for 26,829 shares valued at $854,772 was made by Shafer Bradford J on Friday, March 3.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.